Treatment of blood hyperviscosity with calcium dobesilate in patients with diabetic retinopathy

Ophthalmic Res. 1985;17(3):131-8. doi: 10.1159/000265364.


This double-blind randomized trial was carried out on 37 patients with diabetic retinopathy and blood hyperviscosity. 19 patients received calcium dobesilate in capsules of 500 mg 3 times daily for 3 months and 18 patients took 3 placebo capsules daily during the same period. Calcium dobesilate was found to reduce whole-blood viscosity in a statistically significant manner which was accompanied by a diminution of the albumin/globulin ratio and a significant reduction of fibrinogen and cholesterol levels. A statistically significant diminution of capillary fragility was also observed in the calcium dobesilate-treated group. These results indicate that calcium dobesilate, by restoring the integrity of the microvessels, and by lowering blood viscosity, could act favorably on the evolution of diabetic retinopathy.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Aged
  • Benzenesulfonates / therapeutic use*
  • Blood Viscosity / drug effects*
  • Calcium Dobesilate / therapeutic use*
  • Cholesterol / blood
  • Diabetic Retinopathy / drug therapy*
  • Double-Blind Method
  • Female
  • Fibrinogen / analysis
  • Hematocrit
  • Humans
  • Male
  • Middle Aged
  • Serum Albumin / analysis
  • Serum Globulins / analysis


  • Benzenesulfonates
  • Serum Albumin
  • Serum Globulins
  • Calcium Dobesilate
  • Fibrinogen
  • Cholesterol